TY - JOUR
T1 - Pancreatic Cancer–Associated Fibroblasts
T2 - Where Do We Go from Here?
AU - Carpenter, Eileen S.
AU - Vendramini-Costa, Debora Barbosa
AU - Hasselluhn, Marie C.
AU - Maitra, Anirban
AU - Olive, Kenneth P.
AU - Cukierman, Edna
AU - Pasca di Magliano, Marina
AU - Sherman, Mara H.
N1 - ©2024 American Association for Cancer Research.
PY - 2024/11
Y1 - 2024/11
N2 - Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising the tumor microenvironment, of which, cancer-associated fibroblasts (CAF) are a prevalent component. Despite the gains in understanding of their heterogeneity and functionality from CAF studies in recent years, there are many unanswered questions surrounding this diverse population of cells. Here, we summarize the views of several experts in the field, focusing on the current understanding of CAFs and challenges to address.
AB - Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising the tumor microenvironment, of which, cancer-associated fibroblasts (CAF) are a prevalent component. Despite the gains in understanding of their heterogeneity and functionality from CAF studies in recent years, there are many unanswered questions surrounding this diverse population of cells. Here, we summarize the views of several experts in the field, focusing on the current understanding of CAFs and challenges to address.
KW - Animals
KW - Cancer-Associated Fibroblasts/pathology
KW - Carcinoma, Pancreatic Ductal/pathology
KW - Humans
KW - Pancreatic Neoplasms/pathology
KW - Tumor Microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85208513411&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-24-2860
DO - 10.1158/0008-5472.CAN-24-2860
M3 - Article
C2 - 39283867
SN - 0008-5472
VL - 84
SP - 3505
EP - 3508
JO - Cancer Research
JF - Cancer Research
IS - 21
ER -
